Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5772-5780

  Yoshida, Akira ^a   Takemura, Haruyuki ^a   Inoue, Hitoshi ^a   Miyashita, Toshiyuki ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BUTHIONINE SULFOXIMINE; CAMPTOTHECIN DERIVATIVE; CASPASE 3; CASPASE 7; CYTOCHROME C; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GLUTATHIONE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN; PROTEIN BCL 2; PROTEIN NOXA; PROTEIN P53; PROTEIN P53 UP REGULATED MODULATOR OF APOPTOSIS; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME RELEASE; GENE OVEREXPRESSION; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BUTHIONINE SULFOXIMINE; CAMPTOTHECIN; CASPASE 3; CASPASE 7; CASPASES; CELL DEATH; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ETOPOSIDE; GENE EXPRESSION REGULATION, LEUKEMIC; GLUTATHIONE; HUMANS; LEUKEMIA, PRE-B-CELL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33745227267     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3916     Document Type: Article

References (42)

1. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
2. Panaretakis T, Pokrovskaja K, Shoshan MC, et al. Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002;277:44317-26.
3. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.
4. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 2000;6:1029-35.
5. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-30.
6. Zhang L, Yu J, Park BH, et al. Role of BAX in the apoptotic response to anticancer agents. Science 2000;290:989-92.
7. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996;60:23-32.
8. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997;34:9-19.
9. Real PJ, Cao Y, Wang R, et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 2004;64:7947-53.
10. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 2005;435:677-81.
11. Longo VD, Ellerby LM, Bredesen DE, et al. Human Bcl-2 reverses survival defects in yeast lacking superoxide dismutase and delays death of wild-type yeast. J Cell Biol 1997;137:1581-8.
12. Tyurina YY, Tyurin VA, Carta G, et al. Direct evidence for antioxidant effect of Bcl-2 in PC12 rat pheochromocytoma cells. Arch Biochem Biophys 1997;344:413-23.
13. Hockenbery DM, Oltvai ZN, Yin XM, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-51.
14. Kane DJ, Sarafian TA, Anton R, et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993;262:1274-7.
15. Ellerby LM, Ellerby HM, Park SM, et al. Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. J Neurochem 1996;67:1259-67.
16. Meredith MJ, Cusick CL, Soltaninassab S, et al. Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. Biochem Biophys Res Commun 1998;248:458-63.
17. Voehringer DW. BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med 1999;27:945-50.
18. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 1998;111-112:1-14.
19. Schroder CP, Godwin AK, O'Dwyer PJ, et al. Glutathione and drug resistance. Cancer Invest 1996;14:158-68.
20. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diammine- dichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993;268:20116-25.
21. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988;263:17205-8.
22. Troyano A, Fernandez C, Sancho P, et al. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J Biol Chem 2001;276:47107-15.
23. Meijer C, Mulder NH, Timmer-Bosscha H, et al. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 1992;52:6885-9.
24. Meurette O, Lefeuvre-Orfila L, Rebillard A, et al. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {α}-related apoptosis-inducing ligand/anticancer drug combinations. Clin Cancer Res 2005;11:3075-83.
25. Pommier Y, Capranico G, Orr A, et al. Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. J Mol Biol 1991;222:909-24.
26. Pommier Y, Pourquier P, Fan Y, et al. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:83-105.
27. Hiraoka W, Vazquez N, Nieves-Neira W, et al. Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J Clin Invest 1998;102:1961-8.
28. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
29. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8.
30. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94.
31. Yu J, Zhang L, Hwang PM, et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-82.
32. Han J, Flemington C, Houghton AB, et al. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci U S A 2001;98:11318-23.
33. Zhou M, Yeager AM, Smith SD, et al. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995;85:1608-14.
34. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
35. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969;27:502-22.
36. Qi SN, Yoshida A, Ueda T. Activation of caspases-3/7 is dispensable for idarubicin-induced apoptotic DNA fragmentation in human leukemia cells. Int J Oncol 2003;22:1123-8.
37. Yoshida A, Takauji R, Inuzuka M, et al. Role of serine and ICE-like proteases in induction of apoptosis by etoposide in human leukemia HL-60 cells. Leukemia 1996;10:821-4.
38. Takemura H, Urasaki Y, Yoshida A, et al. Simultaneous treatment with 1-β-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res 2001;61:172-7.
39. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86-91.
40. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-8.
41. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003;4:321-8.
42. Erlacher M, Michalak EM, Kelly PN, et al. BH3-only proteins Puma and Bim are rate-limiting for {γ}-radiation and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005;106:4131-8.